An Indian and a German company will collaborate on the manufacturing and commercialisation of immunoglobulin products, including anti-thymocyte globulin used in organ transplantation, with technology transfer to India, the Embassy of India in Berlin said.
The Indian mission facilitated the exchange of a non-disclosure agreement (NDA) between Germany’s Neovii Biotech GmbH and India’s VINS Bioproducts Ltd on the sidelines of the Indo-German Health Leadership Dialogue on October 13, 2026, the embassy said in a post on X on Thursday.
The collaboration will cover immunoglobulin products, including anti-thymocyte globulin, which is used in human organ transplantation and in the treatment of certain blood disorders.
Immunoglobulin collaboration details
The embassy’s post noted that @eoiberlin facilitated the exchange of the NDA between Neovii Biotech GmbH and VINS Bioproducts Ltd during the Indo-German Health Leadership Dialogue organised by the Embassy of India in Berlin on 13 Oct 2026.
